Market Overview

Vivus Tumbles 70% on FDA Disapproval; Piper Jaffray Urges You to Buy Arena (ARNA, VVUS)


The FDA Advisory Committee voted 9 to 7 yesterday against approval of Vivus' (NASDAQ: VVUS) Qnexa, a fat-fighting pill.

Vivus tumbled 60% today on the news to just over $5.

Concerns arose over Qnexa's safety, especially suicide and cardiovascular risk at high doses. Piper Jaffray believes that even if Qnexa is ultimately approved, it would receive a restrictive label that would limit its use.

Piper Jaffray analysts Edward Tenthoff and Chad Messer think Arena Pharmaceuticals (NASDAQ: ARNA) is a good play now that Qnexa has been down-voted.

Arena's Lorcaserin is also a weight-management pill and a direct competitor to Qnexa. Lorcaserin has a clean safety profile, and Piper believes that Lorcaserin is approvable.

Piper Jaffray said, "We reiterate our Overweight rating and $10 price target based on a projected enterprise value of $1.16 billion."

Posted-In: Chad Messer Edward Tenthoff Piper JaffaryAnalyst Color Price Target FDA Analyst Ratings


Related Articles (ARNA + VVUS)

View Comments and Join the Discussion!

Latest Ratings

POWLSidoti & Co.Maintains47.0
XDeutsche BankInitiates Coverage On121.0
WTEBMO CapitalMaintains18.0
DOLBMO CapitalMaintains50.0
NABMO CapitalMaintains69.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Foster Wheeler on a Roll (FWLT)

Inception Headed for No. 1 at the Box Office This Weekend (TWX)